Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a/1b Study of LY4052031 in Advanced or Metastatic Solid Tumors
jRCT2031240303Phase 1Suspended
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of LY4052031 in transitional cell carcinoma (TCC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 9 more (5 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with dose-limiting toxicities (DLTs) and Overall response rate (ORR) by RECIST 1.1. Started Mar 2025; status: suspended.
02
Drugs
LY4052031
03
Conditions
transitional cell carcinoma (TCC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)esophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031240303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240303.